A pretreatment perfusion MRI-based radiomics score, derived from pharmacokinetic parameters (Ktrans, Ve, Slopemax), demonstrated good predictive value for pathologic complete response (pCR) to neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer (AUC = 0.80), and a nomogram combining this score with grade and Ki-67 further improved prediction (AUC = 0.86), showing correlation with tumor immune environment features (57). This evidence concerns the gene MKI67 and neoplasm.